Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02815891 · ClinicalTrials.gov registry record
A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)
A clinical trial of Nonalcoholic Steatohepatitis and Nonalcoholic Fatty Liver, sponsored by Target PharmaSolutions.
- Recruiting
- Registry status
- 15,000
- Enrollment target
- 20
- Study locations
NCT02815891: Recruiting study of Nonalcoholic Steatohepatitis and Nonalcoholic Fatty Liver, sponsored by Target PharmaSolutions.
NCT02815891 is a study of Nonalcoholic Steatohepatitis and Nonalcoholic Fatty Liver that is actively recruiting participants, run by Target PharmaSolutions. The registered enrollment target is 15,000 participants, above the 203-participant average among 30 other Nonalcoholic Steatohepatitis trials with a reported enrollment target (7289% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02815891, a study of Nonalcoholic Steatohepatitis and Nonalcoholic Fatty Liver, is actively recruiting participants, sponsored by Target PharmaSolutions.
- RECRUITING
- Registry status
- 15,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
TARGET-NASH is a longitudinal observational cohort study of patients being managed for NASH and related conditions across the entire spectrum NAFLD in usual clinical practice. TARGET-NASH is a research registry of patients with NAFL or NASH within academic and community real-world practices maintained in order to assess the safety and effectiveness of current and future therapies.
Primary Outcome
A detailed analysis of demographics, concurrent medications, metabolic and cardiovascular co-morbidities, staging of liver disease, and outcomes for patients with NASH managed in diverse clinical settings will serve as an important comparator for subsequent interventions that alter the treatment paradigm for this disease.
Conditions Studied
Study Locations (20)
Florida
- Gastro Florida - Clearwater
- University of Florida Hepatology Research at CTRB - Gainesville
- University of Florida - Gainesville
- UF Health Gastroenterology - Jacksonville
- University of Miami - Miami
- Schiff Center for Liver Disease/University of Miami - Miami
- AdventHealth Diabetes Institute - Orlando
- Advanced Gastroenterology Associates, LLC - Palm Harbor
- Tampa General Medical Group - Tampa
California
- Stanford University - Palo Alto
- California Liver Research Institute - Pasadena
- University of California, Davis - Sacramento
- Silicon Valley Research Institute - San Jose
Connecticut
- Connecticut Gastroenterology - Hartford
- Connecticut Children's Medical Center - Hartford
Georgia
- Atlanta Gastroenterology Associates, LLC - Atlanta
- Emory University - Children's Healthcare of Atlanta - Atlanta
Arizona
- Banner University Medical Center - Phoenix Transplant Center and Advanced Liver Clinic - Phoenix
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
District of Columbia
- Medstar Georgetown Transplant Institute - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15,000 participants |
| Start Date | 2016-07 |
| Est. Completion | 2036-07 |
What NCT02815891 shows while recruiting
NCT02815891 is an observational study that tracks outcomes without assigning an intervention. Its 15,000 participants enrollment target places it among the larger protocols in the corpus, above the 203-participant average among 30 other Nonalcoholic Steatohepatitis trials with a reported enrollment target (7289% higher).
The record links to 2 conditions, with Nonalcoholic Steatohepatitis appearing as the primary indexed condition, and to 0 interventions.
NCT02815891 names 20 study sites across 7 states, led by Florida, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT02815891 about?
NCT02815891 is a clinical study titled "A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)". TARGET-NASH is a longitudinal observational cohort study of patients being managed for NASH and related conditions across the entire spectrum NAFLD in usual clinical practice. TARGET-NASH is a research registry of patients with NAFL or NASH within academic and community real-world practices maintain...
What is the current status of trial NCT02815891?
This trial is currently recruiting. The enrollment target is 15,000 participants. The study started on 2016-07. Estimated completion is 2036-07.
What conditions does trial NCT02815891 study?
This clinical trial studies the following conditions: Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver.
Who is sponsoring clinical trial NCT02815891?
This trial is sponsored by Target PharmaSolutions, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02815891 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nonalcoholic Steatohepatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02815891's enrollment target sits among peer trials
15,000 1st of 30 higher than 30 of 30 other Nonalcoholic Steatohepatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Nonalcoholic Steatohepatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
-
Low-Dose Pioglitazone in Patients With NASH (AIM 2)
RECRUITING · Phase 2
-
Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans
RECRUITING · Phase 2
-
Metabolic Pathology of Pediatric NAFLD
RECRUITING · NA
-
Predicting Outcomes in Nonalcoholic Steatohepatitis With Advanced Fibrosis
RECRUITING
-
Endoscopic Ultrasound Shear Wave Elastography in Patients With Non-alcoholic Fatty Liver Disease
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00857922 · 15,000 participants
Neurosciences Research Repository
- NCT01137643 · 15,000 participants
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
- NCT01550575 · 15,000 participants
Patient Retrospective Outcomes (PRO)
- NCT02253251 · 15,000 participants
Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia